Young women with polycystic liver disease respond best to somatostatin analogues: A pooled analysis of individual patient data

Gastroenterology

Volumn 145, Issue 2, 2013, Pages

  Gevers, Tom J G ^a   Inthout, Joanna ^a   Caroli, Anna ^b   Ruggenenti, Piero ^b,c   Hogan, Marie C ^d   Torres, Vicente E ^d   Nevens, Frederik ^e   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d MAYO CLINIC   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Liver Cysts PCLD ADPKD Drug Therapy

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ARTICLE; FEMALE; HUMAN; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84880587376     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.04.055     Document Type: Article

References (34)

1. J.P. Drenth, M. Chrispijn, and D.M. Nagorney Medical and surgical treatment options for polycystic liver disease Hepatology 52 2010 2223 2230
2. M. Strazzabosco, and S. Somlo Polycystic liver diseases: congenital disorders of cholangiocyte signaling Gastroenterology 140 2011 1855 1859 1859 e1
3. S. Davila, L. Furu, and A.G. Gharavi Mutations in SEC63 cause autosomal dominant polycystic liver disease Nat Genet 36 2004 575 577
4. J.P. Drenth, R.H. te Morsche, and R. Smink Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease Nat Genet 33 2003 345 347
5. V.E. Torres, and P.C. Harris Autosomal dominant polycystic kidney disease: the last 3 years Kidney Int 76 2009 149 168
6. J.P. Drenth, J.A. Martina, and R.H. Te Morsche Molecular characterization of hepatocystin, the protein that is defective in autosomal dominant polycystic liver disease Gastroenterology 126 2004 1819 1827
7. G. Garcea, A. Rajesh, and A.R. Dennison Surgical management of cystic lesions in the liver ANZ J Surg 2013 Jan 14 http://dx.doi.org/10.1111/ans.12049 [Epub ahead of print]
8. T.J. Gevers, and J.P. Drenth Diagnosis and management of polycystic liver disease Nat Rev Gastroenterol Hepatol 10 2013 101 108
9. F. Que, D.M. Nagorney, and J.B. Gross Jr. Liver resection and cyst fenestration in the treatment of severe polycystic liver disease Gastroenterology 108 1995 487 494
10. T.V. Masyuk, A.I. Masyuk, and V.E. Torres Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate Gastroenterology 132 2007 1104 1116
11. T.V. Masyuk, B.N. Radtke, and A.J. Stroope Pasireotide is more effective than octreotide in reducing hepato-renal cystogenesis in rodents with polycystic kidney and liver diseases Hepatology 2012 Nov 21 http://dx.doi.org/10.1002/hep. 26140 [Epub ahead of print]
12. A. Caroli, L. Antiga, and M. Cafaro Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide Clin J Am Soc Nephrol 5 2010 783 789
13. M.C. Hogan, T.V. Masyuk, and L.J. Page Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease J Am Soc Nephrol 21 2010 1052 1061
14. L. van Keimpema, F. Nevens, and R. Vanslembrouck Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial Gastroenterology 137 2009 1661 1668
15. P. Ruggenenti, A. Remuzzi, and P. Ondei Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease Kidney Int 68 2005 206 216
16. T.J. Gevers, and J.P. Drenth Somatostatin analogues for treatment of polycystic liver disease Curr Opin Gastroenterol 27 2011 294 300
17. K.T. Bae, F. Zhu, and A.B. Chapman Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort Clin J Am Soc Nephrol 1 2006 64 69
18. L. van Keimpema, D.B. de Koning, and B. van Hoek Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases Liver Int 31 2011 92 98
19. J.P. Higgins, D.G. Altman, and P.C. Gotzsche The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
20. L. Antiga, M. Piccinelli, and G. Fasolini Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report Clin J Am Soc Nephrol 1 2006 754 760
21. L. van Keimpema, J.P. Ruurda, and M.F. Ernst Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5% J Gastrointest Surg 12 2008 477 482
22. I.A. Hoevenaren, R. Wester, and R.W. Schrier Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease Liver Int 28 2008 264 270
23. A.B. Chapman Cystic disease in women: clinical characteristics and medical management Adv Ren Replace Ther 10 2003 24 30
24. P.A. Gabow, A.M. Johnson, and W.D. Kaehny Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease Hepatology 11 1990 1033 1037
25. R. Sherstha, C. McKinley, and P. Russ Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease Hepatology 26 1997 1282 1286
26. D. Alvaro, G. Alpini, and P. Onori Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats Gastroenterology 119 2000 1681 1691
27. D. Alvaro, P. Onori, and G. Alpini Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease Am J Pathol 172 2008 321 332
28. D. Djordjijevic, J. Zhang, and M. Priam Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures Endocrinology 139 1998 2272 2277
29. M. Chrispijn, F. Nevens, and T.J. Gevers The long-term outcome of patients with polycystic liver disease treated with lanreotide Aliment Pharmacol Ther 35 2012 266 274
30. M.C. Hogan, T.V. Masyuk, and L. Page Somatostatin analog therapy for severe polycystic liver disease: results after 2 years Nephrol Dial Transplant 27 2012 3532 3539
31. T. Schnelldorfer, V.E. Torres, and S. Zakaria Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation Ann Surg 250 2009 112 118
32. N. Chandok Polycystic liver disease: a clinical review Ann Hepatol 11 2012 819 826
33. M. Andries, D. Glintborg, and A. Kvistborg A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly Clin Endocrinol (Oxford) 68 2008 473 480
34. S.W. van Thiel, J.A. Romijn, and N.R. Biermasz Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients Eur J Endocrinol 150 2004 489 495